Trending

Alzheimer’s disease

AC Immune trials Alzheimer’s vaccine

AC Immune trials Alzheimer’s vaccine

Switzerland’s AC Immune biopharma has begun mid-stage trials of a vaccine against Alzheimer’s disease and Abeta-related cognitive decline

X

AC Immune trials Alzheimer’s vaccine

https://pharmaphorum.com/news/ac-immune-trials-alzheimers-vaccine/

Philanthropists donate $30m towards finding Alzheimer’s cure

Philanthropists donate $30m towards finding Alzheimer’s cure

A coalition of philanthropists has announced they are donating more than $30 million in a drive to combat

X

Philanthropists donate $30m towards finding Alzheimer’s cure

https://pharmaphorum.com/news/philanthropists-donate-30m-towards-finding-alzheimers-cure/

Hope for Alzheimer’s treatment after promising study results

Hope for Alzheimer’s treatment after promising study results

Biogen and Eisai said their latest clinical study confirmed the amyloid hypothesis and might lead to the first

X

Hope for Alzheimer’s treatment after promising study results

https://pharmaphorum.com/news/alzheimers-disease-promising-study/

Eisai accelerates dementia drug discovery research

Eisai accelerates dementia drug discovery research

Eisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the

X

Eisai accelerates dementia drug discovery research

https://pharmaphorum.com/news/eisai-dementia-drug-research/

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase

X

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

https://pharmaphorum.com/news/astrazeneca-lillys-alzheimers-drug/

New HQ to be flagship for UK’s dementia research

New HQ to be flagship for UK’s dementia research

The UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in

X

New HQ to be flagship for UK’s dementia research

https://pharmaphorum.com/news/new-hq-flagship-uks-dementia-research/

AbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’s

AbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’s

Partnership will use novel approach to treating Alzheimer’s.

X

AbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’s

https://pharmaphorum.com/news/abbvie-immunoneurology-alzheimers/

Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chances

Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chances

Biogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a

X

Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chances

https://pharmaphorum.com/news/biogen-sees-spinraza-slow-q3/

Non-drug approaches show promise against Alzheimer’s

Non-drug approaches show promise against Alzheimer’s

The NeuroEM 1000 prevented and reversed memory loss in mice.

X

Non-drug approaches show promise against Alzheimer’s

https://pharmaphorum.com/news/first-kind-alzheimers-wearable-begins-human-trials/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com